# A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

> **NCT04540796** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 147 (actual)

## Conditions studied

- Lymphoma, Non-Hodgkin
- Leukemia, Lymphocytic, Chronic, B-Cell

## Interventions

- **DRUG:** JNJ-75348780

## Key facts

- **NCT ID:** NCT04540796
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-20
- **Primary completion:** 2025-09-09
- **Final completion:** 2025-09-09
- **Target enrollment:** 147 (ACTUAL)
- **Last updated:** 2025-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04540796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04540796, "A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04540796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*